At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 67 enrolled
Drug / intervention
Ipatasertib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of GDC-0973 and GDC-0068 in Patients With Locally Advanced or Metastatic Solid Tumors
In Brief
A Phase 1 clinical trial evaluating Ipatasertib and Cobimetinib for Neoplasms. Completed, enrolled 67 participants across 5 sites in 2 countries.
Detailed Summary
This open-label, multicenter, Phase Ib dose-escalation study will evaluate the safety, tolerability and pharmacokinetics of oral dosing of GDC-0973 and GDC-0068 administered in combination in patients with locally advanced or metastatic solid tumors. Cohorts of patients will receive multiple ascending doses of GDC-0973 and GDC-0068. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms
CountriesSpain, United States
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartApr 2012
Primary CompletionJan 2015
TodayJul 2026
First PostedMar 23, 2012
Enrollment StartApr 1, 2012
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.3 years ago
Interventions
Ipatasertibdrug
multiple doses
Cobimetinibdrug
multiple doses